Long-term effectiveness and safety of deucravacitinib in psoriasis: A 52-week real-world study of genital, scalp, and nail lesions.

Background: The long-term (around 1-year) effectiveness and safety of deucravacitinib for the treatment of psoriasis have not been extensively studied in real-world settings, particularly in difficult-to-treat areas, such as the genital, scalp, and nail regions.

Objectives: To evaluate the 52-week real-world effectiveness and safety of deucravacitinib in patients with moderate-to-severe psoriasis of the genital, scalp, and nail regions.

Methods: This prospective study analyzed 104 patients with moderate-to-severe plaque psoriasis treated with deucravacitinib. Clinical scores, psoriasis area and severity index (PASI), static or regional physician's global assessment (PGA), dermatology life quality index (DLQI), and laboratory inflammatory indices were assessed during a 52-week period.

Results: Deucravacitinib decreased clinical severity scores, and the decrease was sustained for 52 weeks. At week 52, 86.0%, 62.8%, and 25.6% of patients achieved PASI 75, 90, and 100, respectively. Deucravacitinib reduced the PGA scores for the genital, scalp, and nail regions, as well as the DLQI. The 52-week treatment had no impact on laboratory inflammatory indices, and no severe or lethal adverse events were reported.

Conclusions: Deucravacitinib may be a promising long-term treatment option for psoriasis, demonstrating sustained effectiveness and safety, including in difficult-to-treat areas, such as the genital, scalp, and nail regions, in real-world clinical practice.